{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:59:39Z","timestamp":1792616379026,"version":"4.5.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Rosacea is a chronic inflammatory facial dermatosis with incompletely elucidated pathogenesis. LL37 is a key molecular mediator in rosacea development, and mast cells represent pivotal immune players in this process. However, the precise mechanism underlying LL37-induced mast cell degranulation remains undefined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A LL37-induced rosacea-like dermatitis mouse model was established with or without ruxolitinib treatment. Hematoxylin-eosin and toluidine blue staining were used to evaluate the pathological changes. Mice skin lesions were collected for transcriptome sequencing, Western blot and immunofluorescence. In vitro, the interaction between LL37 and TLR2 on the mast cell membrane surface was detected by co-immunoprecipitation and fluorescence staining. The activation of the TLR2\/MyD88\/JAK2\/STAT3 signaling pathway was investigated using lentivirus-mediated TLR2 knockdown, MyD88 overexpression, combined with JAK2 inhibitor (ruxolitinib). Ten patients underwent VISIA skin analysis system and severity assessment following topical ruxolitinib treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>LL37 induces activation of the TLR2\/JAK2 pathway in mast cells of rosacea-like mice. Ruxolitinib ameliorated cutaneous erythema and reduced mast cell infiltration and degranulation. In vitro experiments demonstrated that LL37 directly binds to TLR2, triggering TLR2\/MyD88 pathway activation and subsequent mast cell degranulation. Mechanistically, MyD88 directly interacts with JAK2 to modulate the JAK2\/STAT3 signaling axis, which governs mast cell degranulation. Topical application of ruxolitinib exhibited clinical efficacy in rosacea patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings collectively demonstrate that LL37 drives mast cell activation and degranulation in rosacea pathogenesis via TLR2\/JAK2\/STAT3 pathway activation, while ruxolitinib effectively suppresses this signaling axis. This study provides novel mechanistic insights and therapeutic strategies for rosacea management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1672021","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T05:15:27Z","timestamp":1764134127000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["LL37-driven mast cell degranulation and inflammation in rosacea via TLR2\/JAK2\/STAT3 axis"],"prefix":"10.3389","volume":"16","author":[{"given":"Huiping","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mogen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.037","article-title":"Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee","volume":"78","author":"Gallo","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1506630","article-title":"Rosacea","volume":"377","author":"Van Zuuren","year":"2017","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16481","article-title":"Incidence and prevalence of rosacea: a systematic review and meta-analysis","volume":"179","author":"Gether","year":"2018","journal-title":"Br J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.12.008","article-title":"Association of rosacea with depression and anxiety: A systematic review and meta-analysis","volume":"299","author":"Chang","year":"2022","journal-title":"J Affect Disord"},{"key":"B5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2009.04.007","article-title":"The molecular pathology of rosacea","volume":"55","author":"Yamasaki","year":"2009","journal-title":"J Dermatol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.351","article-title":"TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes","volume":"131","author":"Yamasaki","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nm1616","article-title":"Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea","volume":"13","author":"Yamasaki","year":"2007","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jdermsci.2015.12.006","article-title":"The role of altered cutaneous immune responses in the induction and persistence of rosacea","volume":"82","author":"Margalit","year":"2016","journal-title":"J Dermatol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2014.55.6.1648","article-title":"Increased expression of cathelicidin by direct activation of protease-activated receptor 2: possible implications on the pathogenesis of rosacea","volume":"55","author":"Kim","year":"2014","journal-title":"Yonsei Med J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14164","article-title":"Murine models of rosacea: a review","volume":"21","author":"Zhang","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00597-7","article-title":"Mast cell stabilizers in the treatment of rosacea: A review of existing and emerging therapies","volume":"11","author":"Marchitto","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B12","article-title":"Cutaneous and ocular rosacea: Common and specific physiopathogenic mechanisms and study models","volume":"27","author":"Rodrigues-Braz","year":"2021","journal-title":"Mol Vis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00324","article-title":"The theranostics role of mast cells in the pathophysiology of rosacea","volume":"6","author":"Wang","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-007-0816-z","article-title":"A study of the pathogenesis of rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process","volume":"300","author":"Aroni","year":"2008","journal-title":"Arch Dermatol Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.222","article-title":"Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea","volume":"134","author":"Muto","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4110\/in.2021.21.e18","article-title":"Toll-like receptor 2 in autoimmune inflammation","volume":"21","author":"Marks","year":"2021","journal-title":"Immune Netw"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.650779","article-title":"TLR2 regulates mast cell IL-6 and IL-13 production during listeria monocytogenes infection","volume":"12","author":"Soria-Castro","year":"2021","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2021.1905668","article-title":"Myeloid differentiation factor 88 expression in eyelid specimens of rosacea","volume":"41","author":"Wladis","year":"2022","journal-title":"Orbit"},{"key":"B19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/gene.2010.35","article-title":"Mast cell homeostasis and the JAK-STAT pathway","volume":"11","author":"Morales","year":"2010","journal-title":"Genes Immun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00453","article-title":"Vesicular trafficking and signaling for cytokine and chemokine secretion in mast cells","volume":"5","author":"Blank","year":"2014","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1805474115","article-title":"Raf kinase inhibitor protein negatively regulates Fc\u03f5RI-mediated mast cell activation and allergic response","volume":"115","author":"Lin","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.3390\/ijms24021564","article-title":"Exploring mast cell-CD8 T cell interactions in inflammatory skin diseases","volume":"24","author":"Chen","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.3390\/ijms24087021","article-title":"The role of mast cells in the induction and maintenance of inflammation in selected skin diseases","volume":"24","author":"Wo\u017aniak","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cellimm.2014.12.006","article-title":"Human-derived cathelicidin LL-37 directly activates mast cells to proinflammatory mediator synthesis and migratory response","volume":"293","author":"B\u0105bolewska","year":"2015","journal-title":"Cell Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2023.1122134","article-title":"Neurogenic rosacea could be a small fiber neuropathy","volume":"4","author":"Li","year":"2023","journal-title":"Front Pain Res (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jdermsci.2018.12.004","article-title":"Botulinum toxin blocks mast cells and prevents rosacea like inflammation","volume":"93","author":"Choi","year":"2019","journal-title":"J Dermatol Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s12967-023-04293-2","article-title":"Pharmacological inhibition of demethylzeylasteral on JAK-STAT signaling ameliorates vitiligo","volume":"21","author":"Chang","year":"2023","journal-title":"J Transl Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116746","article-title":"Centella asiatica alleviates psoriasis through JAK\/STAT3-mediated inflammation: An in vitro and in vivo study","volume":"317","author":"Lin","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1273182","article-title":"Epidermal keratinocyte-specific STAT3 deficiency aggravated atopic dermatitis-like skin inflammation in mice through TSLP upregulation","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18263","article-title":"The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.jaad.2024.06.012","article-title":"JAAD Game Changers: Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"91","author":"Grant-Kels","year":"2024","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1672021\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T05:15:29Z","timestamp":1764134129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1672021\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2025.1672021"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1672021","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"article-number":"1672021"}}